Significantly higher rate of improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with mild AD Improvement in cognition measured by ADAS-Cog 11 at three months is ...
On Monday April 29, Annovis Bio announced their phase 2/3 Alzheimer's Disease trial results, causing stock to drop ~60%. Of the five pre-specified efficacy endpoints, only ADAS-Cog11 results were ...
Data presented at CTAD showed strong separation from placebo and statistical significance in mild-to-moderate patients on key global, cognitive, and behavioral measures including CDR-SB, ADAS- Cog 11 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results